Innovative Therapeutics Fibralign’s flagship product, BioBridge Collagen Matrix, addresses a significant unmet medical need for secondary lymphedema treatment, offering a promising growth opportunity in the medical device sector focused on chronic disease management.

Strong Regulatory Approvals With CE, KFDA, and initial 510(k) clearance, Fibralign has established compliance in key markets, facilitating international sales expansions and partnerships with global surgical centers.

Strategic Partnerships The long-term distribution agreement with Terumo enhances market reach and provides a scalable channel for product deployment across multiple jurisdictions, creating an entry point for additional collaborative sales efforts.

Recognition & Credibility Winning the MedTech Innovator Award and participating in prestigious startup accelerators like StartX Med and UCSF Rosenman Institute boosts the company's credibility and visibility in the medtech ecosystem, attracting potential investors and partners.

Emerging Market Potential Targeting a global, underserved patient demographic with a novel solution positions Fibralign well for future revenue growth, especially as awareness and adoption of advanced biomedical devices increase in healthcare markets worldwide.